FOLAWEWO AJAYI: Open Payments
NPI 1922632520 · GLOUCESTER CITY, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$953 in 51 payments from 12 companies in 2025. Trend: 2023 $119 · 2024 $98 · 2025 $953
Food & beverage: $953
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $193 |
| Alkermes, Inc. | 8 | $143 |
| Vanda Pharmaceuticals Inc. | 5 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $88 |
| Janssen Pharmaceuticals, Inc | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| E.R. Squibb & Sons, L.L.C. | 4 | $68 |
| Lundbeck LLC | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
Products named: INGREZZA, REXULTI, ARISTADA, FANAPT, CAPLYTA, COBENFY, INVEGA, Qelbree.
Industry payments across NJ — which companies pay providers there.
